Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01612039
Recruitment Status : Completed
First Posted : June 5, 2012
Last Update Posted : September 28, 2016
Information provided by (Responsible Party):
Telsar Pharma Inc.

Brief Summary:

This is a Phase 2, randomized, double-blind, multicenter, parallel, placebo controlled study. Approximately 120 eligible patients with mild-to-moderate active ulcerative colitis will be randomized to double blind treatment of either 1,000 mg twice daily (b.i.d.) ASP3291 (2,000 mg/d) or matching placebo in a 1:1 ratio for 8 weeks.

The study hypothesis is that treatment with ASP3291 compared to placebo will improve a patient's ulcerative colitis endoscopic score from baseline to Week 8.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: ASP3291 Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled, Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of ASP3291 in Patients With Active Ulcerative Colitis
Study Start Date : July 2012
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: ASP3291 Drug: ASP3291
Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
Placebo Comparator: Placebo Drug: Placebo
Matching placebo tablets

Primary Outcome Measures :
  1. Change from baseline (Visit 2) to Week 8 (Visit 7) in Modified Baron Score [ Time Frame: Baseline to Week 8 ]

Secondary Outcome Measures :
  1. Proportion of subjects with Modified Baron Score of 0 or 1 at Week 8 (Visit 7) [ Time Frame: Week 8 ]
  2. Change in Ulcerative Colitis Clinical Score of >3 [ Time Frame: Basline to Week 8 ]
  3. Ulcerative Colitis Clinical Score stool frequency and rectal bleeding score of 0 [ Time Frame: Week 8 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented diagnosis of ulcerative colitis by endoscopy and histology consistent with diagnosis
  • Must be able to provide informed consent
  • Has a Modified Baron Score of at least 2 (as determined by the investigator) at 15 cm or more from the anal verge as assessed during the screening period
  • Has an Ulcerative Colitis Clinical Score (UCCS) of at least 4, with a stool frequency and rectal bleeding score of at least 1 as assessed during the screening period
  • If female, is at least 2 years postmenopausal, surgically sterile per documentation provided by a medical professional, agrees to sexual abstinence, or uses two approved highly effective methods of birth control during the study period and for 30 days after the last dose of study drug
  • If male, agrees to sexual abstinence or to use two highly effective methods of birth control during the study period and for 90 days after last dose; agrees to not donate sperm during the study period and for 90 days after last dose
  • Willing and able to comply with the study requirements

Exclusion Criteria:

  • Has a history of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would preclude participation in the study
  • Has severe Ulcerative Colitis as defined by an average bloody stool frequency of >6 per day and at least one of the following:

    • Resting heart rate >90 bpm
    • Oral temperature of >38°C (>100.4°F)
    • Hemoglobin of <10.5 g/dL
  • Has has undergone previous resective colonic surgery
  • Has a significant or immediate risk for toxic megacolon
  • Has previous diagnosis with Crohn's disease, indeterminate colitis, microscopic colitis or acute diverticulitis based on medical history
  • Has an extension of disease limited to ulcerative proctitis (i.e., disease extension less than 15 cm from the anal verge)
  • Has an active peptic ulcer disease based on medical history
  • Shows a stool culture positive for enteric pathogens during the screening period
  • Had previous treatment with tumor necrosis factor-α (TNF α) inhibitors
  • Had treatment with rectal corticosteroid within 2 weeks before Day -2
  • Has active liver disease or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times the upper limit of normal (ULN) at screening
  • Has an estimated glomerular filtration rate (using Cockroft-Gault formula corrected for body surface area) of <60 mL/min at screening
  • Known history of human immunodeficiency virus antibody
  • History of severe allergic or anaphylactic reactions requiring medical attention
  • Has participated in another investigational study within 30 days before Visit 3
  • History of drug or alcohol abuse in the past 2 years
  • Has previously participated in a study with ASP3291

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01612039

Sponsors and Collaborators
Telsar Pharma Inc.
Study Director: Robert Schinagl, Ph.D. Drais Pharmaceuticals, Inc.

Responsible Party: Telsar Pharma Inc. Identifier: NCT01612039     History of Changes
Other Study ID Numbers: 3291-CL-0004
First Posted: June 5, 2012    Key Record Dates
Last Update Posted: September 28, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Telsar Pharma Inc.:
ulcerative colitis

Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases